Over the last 8 years Scotland has made a very significant investment in building the human and physical infrastructure required to leverage our leading position in the field of stem cell biology to support the development of a thriving Scottish Regenerative Medicine industrial sector. This initial investment is nearing completion, has substantially delivered and has started to make a real impact. However its full value will only be realised as the world-wide regenerative medicine sector matures and near term scientific, technical and industrial impediments are overcome. Our competitors in other parts of the UK and across the world are continuing to invest in this space in order to imbue their nascent industries with comparative advantage.
With these considerations in mind the community has undertaken a review of the current state of play, in order to determine what now needs to be done in order to drive the growth of the Regenerative Medicine industry in Scotland and embed significant long-term benefits to the economy and health of the nation.
This document sets out a strategy which has been developed in collaboration with the academic, business and clinical communities. It is intended for high-level discussion and to provide a framework for future collective direction and investment.
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies. The Company is developing a pharmaceutical pipeline to improve drug delivery technologies and capabilities for patients, physicians, and payers through transdermal delivery technologies. Nutriband’s lead product is its AVERSA® technology. AVERSA® abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with patent prosecution in the US and Canada. Nutriband has made sure to target all large applicable markets and its global patent protection has opened up many opportunities for the Company to make a big impact on the safety profile of drugs globally.
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market NarayanSharma67
The “Global mRNA Vaccines and Therapeutics Market” is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26, says MarkNtel Advisors. The market growth essentially attributes to the rising prevalence of infectious and chronic diseases, including HIV, diabetes, cancer, and cardiovascular diseases.
Market Exclusivity Under the Waxman-Hatch ActMichael Swit
March 19, 2007 presentation to the San Diego County Bar Association IP Section, with a focus on:
•Orphan Drug Exclusivity (Seven Years)
•Five-Year Exclusivity
•Three-Year Exclusivity
•Pediatric Exclusivity (Six Months)
•180-Day Exclusivity
NEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGESganpat420
Abstract
Introduction
Global pharmaceutical industry
Indian pharmaceutical industry
Indian Pharmaceutical Market
Opportunities
Challenges
Conclusion
References
Pharma leader series top stem cell technology companies 2015 2025Visiongain
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976)
or refer to our website: http://goo.gl/bhNICQ
Regulatory Strategies for Medical Device Companies to Succeed in AsiaPacific Bridge Medical
This whitepaper provides an overview of strategies for medical device companies to succeed in Asia. Included is key market strategy information on China, Singapore, India, and Hong Kong. Also included is information on regulations, government regulatory bodies, device classification, product standard and type testing, product registration requirements and clinical trials.
For more information, contact us for a free 15 minute consultation at http://www.pacificbridgemedical.com/contact-us/.
Hi
I am Rahul Ranjan Rai, perusing MBA from Jaypee Business School and I have completed this Project under the supervision of Pro. Evan Costle (france). I hope this presentation will help you to understand the emerging concepts in Generic Industry
Thank you
Regards
Rahul
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Over the last 8 years Scotland has made a very significant investment in building the human and physical infrastructure required to leverage our leading position in the field of stem cell biology to support the development of a thriving Scottish Regenerative Medicine industrial sector. This initial investment is nearing completion, has substantially delivered and has started to make a real impact. However its full value will only be realised as the world-wide regenerative medicine sector matures and near term scientific, technical and industrial impediments are overcome. Our competitors in other parts of the UK and across the world are continuing to invest in this space in order to imbue their nascent industries with comparative advantage.
With these considerations in mind the community has undertaken a review of the current state of play, in order to determine what now needs to be done in order to drive the growth of the Regenerative Medicine industry in Scotland and embed significant long-term benefits to the economy and health of the nation.
This document sets out a strategy which has been developed in collaboration with the academic, business and clinical communities. It is intended for high-level discussion and to provide a framework for future collective direction and investment.
Nutriband is a transdermal focused pharmaceutical company based in the United States with a goal to improve the safety, comfort and efficacy of existing drugs using transdermal technologies. The Company is developing a pharmaceutical pipeline to improve drug delivery technologies and capabilities for patients, physicians, and payers through transdermal delivery technologies. Nutriband’s lead product is its AVERSA® technology. AVERSA® abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential, such as opioids. The Company’s first application for AVERSA® is an abuse deterrent fentanyl transdermal patch which it is developing to provide clinicians and patients a safe extended-release patch for chronic pain. The goal is to make opioid based pain treatments safe for all who need them. AVERSA technology has received patent protection in the European Union, Australia, Japan, Mexico, Russia with patent prosecution in the US and Canada. Nutriband has made sure to target all large applicable markets and its global patent protection has opened up many opportunities for the Company to make a big impact on the safety profile of drugs globally.
COVID-19 Impacts on the Global mRNA Vaccines and Therapeutics Market NarayanSharma67
The “Global mRNA Vaccines and Therapeutics Market” is likely to grow at a CAGR of around 13% during the forecast period, i.e., 2021-26, says MarkNtel Advisors. The market growth essentially attributes to the rising prevalence of infectious and chronic diseases, including HIV, diabetes, cancer, and cardiovascular diseases.
Market Exclusivity Under the Waxman-Hatch ActMichael Swit
March 19, 2007 presentation to the San Diego County Bar Association IP Section, with a focus on:
•Orphan Drug Exclusivity (Seven Years)
•Five-Year Exclusivity
•Three-Year Exclusivity
•Pediatric Exclusivity (Six Months)
•180-Day Exclusivity
NEW ERA OF DRUG PRODUCT: OPPORTUNITIES AND CHALLENGESganpat420
Abstract
Introduction
Global pharmaceutical industry
Indian pharmaceutical industry
Indian Pharmaceutical Market
Opportunities
Challenges
Conclusion
References
Pharma leader series top stem cell technology companies 2015 2025Visiongain
For an Executive Summary of this report please contact ben.suntivarakom@visiongain.com
(+44 (0)20 7549 9976)
or refer to our website: http://goo.gl/bhNICQ
Regulatory Strategies for Medical Device Companies to Succeed in AsiaPacific Bridge Medical
This whitepaper provides an overview of strategies for medical device companies to succeed in Asia. Included is key market strategy information on China, Singapore, India, and Hong Kong. Also included is information on regulations, government regulatory bodies, device classification, product standard and type testing, product registration requirements and clinical trials.
For more information, contact us for a free 15 minute consultation at http://www.pacificbridgemedical.com/contact-us/.
Hi
I am Rahul Ranjan Rai, perusing MBA from Jaypee Business School and I have completed this Project under the supervision of Pro. Evan Costle (france). I hope this presentation will help you to understand the emerging concepts in Generic Industry
Thank you
Regards
Rahul
Public Device & Biopharma Ophthalmology Company Showcase - pSividaHealthegy
Public Device & Biopharma Ophthalmology Company Showcase - pSivida at OIS@AAO 2016.
Presenter:
Nancy Lurker, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
OneMedForum New York 2010 - Company Presentation. Access Pharmaceuticals, Inc., a emerging biopharmaceutical company that focuses on adding value to exciting product concepts in research by advancing those products through clinical development.
Regenerative Medicine Industry Outlook 2014Pete Shuster
This is an excellent presentation on companies and products that are making their mark on the Regenerative Medicine Market. The outlook for 2014 is encouraging.
Presentation from OIS@ASCRS 2016
Co-Moderators:
Gilbert H. Kliman, MD, Managing Director – InterWest Partners
Stephen Slade, MD
Company Presentations
Equinox | John Berdahl, MD, Founder & CEO
Presbyopia Therapies | Jim McCollum, Co-Founder
Stroma Medical | Doug Daniels, CEO
Eyenovia | Curt LaBelle, MD, Director
Wicab | Robert Beckman, President & COO
Oncology biosimilars Market Report in PPT: Top Companies, Trends and Future D...IMARC Group
According to the latest report by IMARC Group,the global oncology biosimilars market exhibited strong growth during 2015-2020.
Oncology biosimilars are cost-effective counterparts of the already licensed reference biologics.
Organ Preservation Market PPT: Demand, Trends and Business Opportunities 2022-27IMARC Group
The global organ preservation market reached a value of US$ 163.5 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 242.6 Million by 2027, exhibiting at a CAGR of 6.8% during 2022-2027.
More info:- https://www.imarcgroup.com/organ-preservation-market
Organ Preservation Market PPT: Demand, Trends and Business Opportunities 2022-27IMARC Group
Looking forward, the organ preservation market value is projected to reach a strong growth during the forecast period (2022-2027).
More info:- https://www.imarcgroup.com/organ-preservation-market
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Dócola is a social good organization with the only free care communication platform that consolidates thousands of free and low-cost patient education resources from the leading nonprofit, government, and commercial organizations in one marketplace. Plus, you can easily create and upload your own resources.
INNO HOLDINGS INC. is an innovative building-technology company with a mission to transform the construction industry with our proprietary cold-formed steel- framing technology and other building innovations
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a global innovation company focused on discovering and developing precision medicine innovations and deploying them into high-performing businesses. Aditxt’s diverse innovation portfolio includes: Adimune™, Inc., developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir™, Inc., focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta™, Inc., offering convenient, rapid, personalized, and high-quality lab testing —anytime and anywhere at its CLIA certified and CAP accredited clinical laboratory based in Richmond, VA.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
MUTUAL FUNDS (ICICI Prudential Mutual Fund) BY JAMES RODRIGUESWilliamRodrigues148
Mutual funds are investment vehicles that pool money from multiple investors to purchase a diversified portfolio of stocks, bonds, or other securities. They are managed by professional portfolio managers or investment companies who make investment decisions on behalf of the fund's investors.
2. Safe Harbor Statement
This Overview contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the
words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and
uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, AMI's ability to successfully
execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions,
effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and
manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in
components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and
changes, and various other factors beyond the Company's control.
This Overview does not purport to be all-inclusive or to contain all the information that the recipient may desire in evaluating the Company. This Overview does not constitute an offer
to sell any securities or a solicitation of an offer to purchase any securities. Except as otherwise indicated herein, information is presented as of August 1, 2017. The delivery of this
Overview after this date does not imply there has been no change in the affairs of the Company after the date hereof. The Company is under no obligation to update this Overview.
Certain information contained in this Overview has been obtained by the Company and/or its officers and directors from sources deemed reliable by the Company. Such information
necessarily incorporates significant assumptions and estimates as well as factual matters. No representation or warranty is made by AMI that it will be able to: (i) implement the
business plan discussed herein, or any of it; (ii) achieve the operating or sale results discussed herein, or any of them; or (iii) operate in a manner which permits AMI’s securities to retain
their value or appreciate in value. Any investment in AMI involves risk.
3ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 2
3. Overview
brach·y·ther·a·py
/brakēˈTHerəpē/
noun
the treatment of cancer by the insertion of radioactive implants (isotopes) directly into the tissue – inside or next to the treatment area
AMI is led by a competent team with impressive credentials that believes in strategic partnerships with national labs, universities and
private corporations.
Plans to generate near-term revenue from veterinarian clinics and international licensing while pursuing FDA approval for multiple
cancer indications and offering the potential economics of a drug with the lower cost and shorter approval path of a device.
4ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 3
Advanced Medical Isotope Corporation (AMI) is in the late-stage development of a brachytherapy device for
medical and veterinary cancer treatment applications.
4. The Mission: Provide a new potent brachytherapy tool for the treatment of
cancers in humans and animals that will be very effective in
improving the lives of these patients.
5ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 4
The Strategy: Generate near-term revenue from veterinarian clinics and
international licensing while pursuing FDA approval for multiple
cancer indications.
5. Platform Technology: RadioGel™
Next-generation radiopharmaceutical
therapeutic device.
6ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 5
The Gel delivery vehicle is hydrogel
Liquid at room temperature
Solidifies at body temperature and locks in the particles
The Particle is Yttrium-90 phosphate
Very small size insoluble particles – Perfuses within the
tumor
Highest energy beta emitter – Delivers very high dose to
the tumor
Radiation travels a short distance – Minimal collateral
damage to healthy tissue outside the target region
2.7 day half-life – Only 5% of radiation left after 10 days
Interstitial Injection of RadioGel™
Intra-Arterial Injection of RadioGel™
6. Highlights
Expect revenue from IsoPet by January 2018 or earlier
International licensing revenue expected in early 2018
Strong leadership and world-class Medical Advisory Board
Plan to uplist to senior exchange (NASDAQ or NYSE MKT)
Partnerships with leading national labs, universities, and private corporations
Optimization of proprietary production process complete
FDA ruled that our product is a device - attractive drug economics, with lower
costs and shorter approval pathway of device
Exclusive license and extensive intellectual property protections
7ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 6
7. Initial Market: Veterinary Applications
8ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 7
Obtain approval to
test
Demonstrate
therapies at leading
research universities
Begin sales to
private clinics
8. IsoPet - Multiple Indications
9ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 8
FDA ruled that RadioGel™ is a device for humans. We are now confirming that this
applies to animals to insure that no pre-market approval is required for pet therapy.
Testing at leading university veterinary programs to demonstrate therapy across multiple
indications:
Program guided by Dr. Alice Villalobos – Chair of the Veterinary Medical Advisory Board
Feline Sarcoma Canine Sarcoma
Equestrian Sarcoma
Feline Oral Cancer
Mast Cell Skin Cancer
Prostate Cancer
Liver Cancer
9. Veterinary Market – Significant Opportunity
10ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 9
There are 78 million dogs and 86 million cats in the United States
Cancer is the leading cause of death for 32% of cats and 50% of
dogs over age 10
Treating 10% of the cancers with a $5,000 therapy generates
$40M annual revenue
Revenue stream can begin by January 2018 or earlier
10. RadioGel™ - Potential Human Applications
Medical Advisory Board
More than 125 years combined experience
Input from Mayo Clinic doctors
Selection criteria
Effective in killing cancer cells
Notable advantages over existing therapies
Can be profitably embraced by the medical community
Skin cancer selected for first Indication for Use
11ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 10
• Skin cancer
• Involved lymph nodes
• Liver
• Pancreas
• Head and neck
• Bladder
• Ocular melanoma
• Rectal
• Non-dendritic brain
• Gynecological
• Spinal
• Sino-nasal
• Oropharyngeal
• Recurring esophageal
• Base of tongue
• Localized prostate
• Breast cavity resectomy
• Anaplastic thyroid
11. Basal Cell and Squamous Cell Skin Cancers
Market Projections
One out of every three new cancers is skin cancer
In the US - 5.4 million cases a year (in 3.3 million people)
>4 million – Basal cell carcinoma - in deepest layer of the epidermis
1 million - Squamous cell carcinoma – in upper layers of the epidermis
10% X 3.3 Million X $5K = $1.5 B in annual revenues
Revenue stream can begin in early 2018 via international licensing
12ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 11
12. FDA Path Forward
Engaged John Smith M.D., J.D. from Hogan Lovellis
Using veterinary testing to optimize therapy techniques
Conduct international human testing in parallel
Steps for FDA approval
Pre-submission/meetings with FDA
Bench-top and pre-clinical animal studies
Investigational Device Exemption (IDE) for human trials
Pre-market submission for final FDA app
13ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 12
13. Medical Sector – Growth Strategy
14ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 13
Quantum growth steps will be achieved through a series of new Indications for
Use
Skin Cancer
Lymph Nodes
Liver/Pancreas
14. RadioGel™ Production
The production optimization is completed
Have a proprietary process to cost-effectively produce hydrogel and
very small particles
Currently institutionalizing the procedures with Good
Manufacturing Processes (GMP) and the Quality Assurance Plan as
required by the FDA
15ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 14
15. Intellectual Property Protection
16ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 15
Retained an intellectual property attorney
Battelle sublicensing give AMI rights to eight patents
Potential future patents based on product and process improvements
Trademark protection in 17 countries
Proprietary intellectual property
Production procedures
Advanced product development – resorption time, imaging
All test data
16. Management Team
17ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 16
Dr. Mike Korenko
President & CEO
Former VP of Westinghouse and COO for Curtiss-Wright
Doctor of Science from MIT; NATO Postdoctoral Fellow at Oxford University, and was selected
as a White House Fellow for the Department of Defense, reporting to Secretary Cap
Weinberger. Dr. Korenko currently is the author of 28 patents and has received many awards.
Leonard Bruce Jolliff
Chief Financial Officer
Dr. David J. Swanberg
Chief Technology Officer
Dr. Donald A. Ludwig
Director of Special Projects
Dr. Nigel R. Stevenson
Chief Science Officer
17. Medical & Scientific Advisory Boards
18ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 17
Dr. Barry D. Pressman MD, FACR
Chairman Medical Advisory Board
Dr. Darrell Fisher
Dr. Alan E. Waltar
Chairman Scientific Advisory Board
Dr. Alice Villalobos, DVM, FNAP
Chair of the Veterinary Medicine Advisory Board
Dr. Albert S. DeNittis MD, MS, FCPP Dr. Howard Sandler, MD, MS, FASTRO
Additional Medical Advisory Board members:
18. Key Stock Stats
19ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 18
Exchange: Ticker OTC: ADMD
Price $0.10
Market Cap $5.0M
Shares Outstanding 50.1M
Insider Ownership 3%
Float 48.7 M
52-Range $0.05-$1.00
* Data as of July 18, 2017
19. Highlights
Expect revenue from IsoPet by January 2018 or earlier
International licensing revenue expected in early 2018
Strong leadership and world-class Medical Advisory Board
Plan to uplist to senior exchange (NASDAQ or NYSE MKT)
Partnerships with leading national labs, universities, and private corporations
Optimization of proprietary production process complete
Platform offers attractive drug economics, with lower costs and shorter approval
pathway of device
Exclusive license and extensive intellectual property protections
20ADVANCED MEDICAL ISOTOPE CORPORATION OTC: ADMD 19